What is Wedbush's Estimate for SANA Q3 Earnings?

Key Points

• Wedbush estimates Sana Biotechnology's Q3 2025 earnings per share will be ($0.23), maintaining an "Outperform" rating with a target price of $5.00.
• The consensus estimate for Sana's full-year earnings is (\$1.16) per share, while the average price target among analysts is $7.50.
• Sana Biotechnology's stock has a current market capitalization of $806.18 million and a 52-week trading range between $1.26 and $7.30.

Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Equities researchers at Wedbush issued their Q3 2025 earnings per share (EPS) estimates for shares of Sana Biotechnology in a research report issued to clients and investors on Wednesday, September 24th. Wedbush analyst M. Fan forecasts that the company will post earnings per share of ($0.23) for the quarter. Wedbush currently has a "Outperform" rating and a $5.00 target price on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. Wedbush also issued estimates for Sana Biotechnology's Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.74) EPS, Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.57) EPS, FY2027 earnings at ($0.46) EPS, FY2028 earnings at ($0.44) EPS and FY2029 earnings at ($0.46) EPS.

A number of other equities research analysts also recently weighed in on SANA. Morgan Stanley initiated coverage on Sana Biotechnology in a research note on Thursday, July 3rd. They set an "overweight" rating and a $12.00 price target for the company. JMP Securities reissued a "market outperform" rating and issued a $5.00 price objective on shares of Sana Biotechnology in a research note on Tuesday, June 24th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Sana Biotechnology has an average rating of "Buy" and an average price target of $7.50.

Sana Biotechnology Price Performance

SANA opened at $3.39 on Friday. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The business has a 50-day moving average of $3.57 and a 200-day moving average of $2.75. The company has a market capitalization of $806.18 million, a PE ratio of -3.20 and a beta of 1.88.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Monday, August 11th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.04.

Institutional Trading of Sana Biotechnology

Several institutional investors have recently bought and sold shares of SANA. Pallas Capital Advisors LLC acquired a new position in shares of Sana Biotechnology during the first quarter valued at $29,000. Ameriprise Financial Inc. bought a new stake in Sana Biotechnology in the fourth quarter valued at about $29,000. Nisa Investment Advisors LLC increased its holdings in Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company's stock valued at $30,000 after purchasing an additional 9,501 shares during the last quarter. Hoey Investments Inc. bought a new stake in Sana Biotechnology in the second quarter valued at about $33,000. Finally, BNP Paribas Financial Markets bought a new stake in Sana Biotechnology in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.